Holen Sie sich die Stockscreener-App
0.4695
2.09%
0.0096
Handel nachbörslich:
.46
-0.0095
-2.02%
Turnstone Biologics Corp Aktie (TSBX) Neueste Nachrichten
Turnstone Biologics Faces Financial and Operational Challenges - TipRanks
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan
Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia
Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
Turnstone Biologics Reveals Breakthrough TIL Cancer Treatment Data at SITC 2024 | TSBX Stock News - StockTitan
Warning: TSBX is at high risk of performing badly - MSN
Turnstone Biologics (NASDAQ:TSBX) & Recursion Pharmaceuticals (NASDAQ:RXRX) Critical Contrast - Defense World
BofA downgrades Turnstone stock, citing wait-and-see approach until 2025 data - Investing.com
Turnstone fires most staff in bid to to extend runway - The Pharma Letter
Turnstone Biologics Streamlines Operations and Leadership - Yahoo Finance
Turnstone Biologics announces strategic cuts and focus shift - Investing.com
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway - ForexTV.com
Turnstone Biologics stock plunges to 52-week low of $0.45 - Investing.com
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Update - Defense World
Turnstone Biologics stock hits 52-week low at $0.58 amid sharp decline - Investing.com
Analyzing Organovo (NASDAQ:ONVO) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Reviewing Krystal Biotech (NASDAQ:KRYS) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.67 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $0.67 By Investing.com - Investing.com Canada
Taking on analysts’ expectations and winning: Turnstone Biologics Corp (TSBX) - SETE News
Investor’s Delight: Turnstone Biologics Corp (TSBX) Closes Strong at 0.70, Up 1.15 - The Dwinnex
Is Turnstone Biologics Corp (TSBX) a good investment opportunity? - US Post News
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Increase in Short Interest - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.72 - Investing.com
Turnstone Biologics price target lowered to $10 from $12 at BofA - TipRanks
Tourmaline Bio (NASDAQ:TRML) versus Turnstone Biologics (NASDAQ:TSBX) Head-To-Head Review - Defense World
The time has not yet come to remove your chips from the table: Turnstone Biologics Corp (TSBX) - SETE News
Turnstone Biologics Corp’s results are impressive - US Post News
Turnstone Biologics (NASDAQ:TSBX) Price Target Cut to $3.75 by Analysts at Piper Sandler - Defense World
Turnstone Biologics shares target cut by Piper Sandler with no rating change - Investing.com
TSBX’s Stock Market Adventure: -70.07% YTD Growth Amidst Volatility - The InvestChronicle
Market Momentum: Turnstone Biologics Corp (TSBX) Registers a -8.24 Decrease, Closing at 0.76 - The Dwinnex
Turnstone Biologics price target lowered to $3.75 from $20 at Piper Sandler - TipRanks
SVB Securities slashes price target on Turnstone Biologics Corp [TSBX] – find out why. - The DBT News
Turnstone Biologics (NASDAQ:TSBX) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - Defense World
Take off with Turnstone Biologics Corp (TSBX): Get ready for trading - SETE News
Turnstone Biologics stock plunges to 52-week low of $1.36 By Investing.com - Investing.com Canada
Why Is Turnstone Biologics Stock Trading Lower On Thursday?Turnstone Biologics (NASDAQ:TSBX) - Benzinga
Turnstone Biologics stock plunges to 52-week low of $1.36 - Investing.com
Turnstone reports positive early trial results for cancer therapy - Investing.com
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today? - InvestorPlace
Turnstone Biologics Reports Encouraging Phase 1 Results - TipRanks
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - ForexTV.com
Turnstone Biologics reports Q2 EPS (92c), consensus (93c) - TipRanks
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer - StockTitan
Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts - Insider Monkey
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Down 20.5% in June - MarketBeat
Can you still get a good price for Turnstone Biologics Corp (TSBX) Shares at this point? – US Post News - US Post News
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):